Relationship between HER-2 overexpression and brain metastasis in esophageal cancer patients

Table 1 Characteristics of esophageal cancer patients who underwent esophagectomy

Characteristics	n (%)
Age on diagnosis of esophageal cancer (yr)
Median	64
Range	36-86
Sex
Male	124 (87.3)
Female	18 (12.7)
Smoking
< 100 cigs/life	33 (23.2)
< 10 pack-year	9 (6.3)
> 10 pack-year	87 (61.3)
Unknown	13 (9.2)
Esophageal cancer type (path report)
Adenocarcinoma	118 (83.1)
Squamous cell carcinoma	22 (15.5)
Small cell carcinoma	1 (0.7)
GIST	1 (0.7)
T classification
T1	18 (12.7)
T2	19 (13.4)
T3	76 (53.5)
T4	2 (1.4)
Unknown	27 (19)
N classification
N0	49 (34.5)
N1	65 (45.8)
N2	3 (2.1)
Unknown	25 (17.6)
Neoadjuvant treatment
Neoadjuvant treatment	88 (62)
No neoadjuvant treatment	52 (36.6)
Unknown	2 (1.4)
Response to neoadjuvant treatment
No residual tumor (complete response)	17 (12)
Residual tumor present (partial response)	71 (50)
No neoadjuvant treatment	52 (36.6)
Unknown	2 (1.4)
Tumor grade
Well differentiated	4 (2.8)
Moderately differentiated	67 (47.2)
Poorly differentiated	61 (43)
Unknown	10 (7)
Disease relapse
Yes	43 (30.3)
No	91 (64.1)
Unknown	8 (5.6)

GIST: Gastrointestinal stromal tumor.

Table 2 First site of esophageal cancer relapse following esophagectomy

Relapse site	n (%)
Brain	9 (21)
Peritoneum	3 (7)
Esophageal remnants, paraesophageal lymph nodes or mediastinum (locoregional relapse)	13 (30)
Lungs	8 (19)
Liver	6 (14)
Bone	4 (9)